NBC Securities Inc. Acquires 10,296 Shares of Gilead Sciences, Inc. $GILD

Key Points

• NBC Securities Inc. boosted its stake in Gilead by 150.3%, purchasing 10,296 shares to own 17,147 shares valued at about $2.105 million at quarter-end.
• Gilead beat expectations for the quarter with $1.86 EPS (vs. $1.83) and $7.93B revenue (vs. $7.68B), and set FY2026 guidance of $8.45–$8.85 EPS (consensus ~$8.63).
• Gilead increased its quarterly dividend to $0.82 (annualized $3.28, ~2.5% yield), even as insiders sold shares — including the CEO's 10,000-share sale and 178,640 shares sold by insiders over the last quarter.

NBC Securities Inc. increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 150.3% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 17,147 shares of the biopharmaceutical company's stock after buying an additional 10,296 shares during the quarter. NBC Securities Inc.'s holdings in Gilead Sciences were worth $2,105,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Corundum Trust Company INC bought a new stake in Gilead Sciences in the 3rd quarter worth about $26,000. Financial Consulate Inc. increased its holdings in Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 109 shares in the last quarter. BOCHK Asset Management Ltd bought a new stake in Gilead Sciences in the 4th quarter worth about $31,000. MTM Investment Management LLC increased its holdings in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 176 shares in the last quarter. Finally, Vision Financial Markets LLC increased its holdings in Gilead Sciences by 123.1% in the 4th quarter. Vision Financial Markets LLC now owns 290 shares of the biopharmaceutical company's stock worth $36,000 after buying an additional 160 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $133.64 on Friday. The stock's fifty day moving average is $142.93 and its 200 day moving average is $131.90. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The firm has a market capitalization of $165.88 billion, a PE ratio of 19.74, a PEG ratio of 1.76 and a beta of 0.39. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the prior year, the firm posted $1.90 EPS. Gilead Sciences's quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 8.63 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were paid a $0.82 dividend. The ex-dividend date was Friday, March 13th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences's payout ratio is 48.45%.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the sale, the chief executive officer owned 642,308 shares in the company, valued at $92,999,775.32. This trade represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the completion of the sale, the chief financial officer owned 176,191 shares in the company, valued at approximately $24,835,883.36. The trade was a 1.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 178,640 shares of company stock worth $26,691,550 over the last quarter. Company insiders own 0.30% of the company's stock.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of recent research reports. Truist Financial boosted their price target on Gilead Sciences from $145.00 to $152.00 and gave the company a "buy" rating in a research note on Wednesday, February 11th. Wells Fargo & Company boosted their price target on Gilead Sciences from $150.00 to $165.00 and gave the company an "overweight" rating in a research note on Wednesday, February 11th. Weiss Ratings restated a "buy (b)" rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Scotiabank boosted their price target on Gilead Sciences from $140.00 to $177.00 and gave the company a "sector outperform" rating in a research note on Wednesday, February 11th. Finally, Jefferies Financial Group initiated coverage on Gilead Sciences in a research note on Tuesday, March 10th. They set a "buy" rating and a $180.00 price target for the company. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and an average target price of $157.35.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.